Search Results 101-110 of 18447 for Relapse
... relapse study design. An Open Label Extension Trial of Eculizumab in ... relapses. This observational registry will record feasibility, tolerability ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
A Study of Oral LGH447 in Patients with Relapsed and/or Refractory Multiple Myeloma · Overview · Participation eligibility · Participating Mayo Clinic locations.
It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.
A Study to Assess Older Adults Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality After Allogeneic ...
Aftercare programs and support groups help people recovering from alcohol use disorder to stop drinking, manage relapses and cope with necessary lifestyle ...
Relapse should be expected with multiple myeloma, with each treatment regimen administered offering the patient roughly two to three years of disease control.
Patients with PTCL according to World Health Organization (WHO) criteria and have relapsed or are refractory to at least 1 prior systemic, cytoxic therapy for ...
Clinical Trials · Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma · More about research at Mayo Clinic · Mayo ...
The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.